BeyondSpring (NASDAQ:BYSI) Stock Price Down 7.3% – Should You Sell?

BeyondSpring Inc. (NASDAQ:BYSI) shares traded down 7.3% during mid-day trading on Tuesday . The stock traded as low as $1.66 and last traded at $1.66. Approximately 8,619 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 22,125 shares. The stock had previously closed at $1.79.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

BeyondSpring Price Performance

The firm’s 50 day simple moving average is $1.61 and its two-hundred day simple moving average is $1.61. The firm has a market capitalization of $61.27 million, a P/E ratio of -10.64 and a beta of 0.43.

BeyondSpring (NASDAQ:BYSI) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49.

Hedge Funds Weigh In On BeyondSpring

A hedge fund recently bought a new stake in BeyondSpring stock. State Street Corp acquired a new stake in BeyondSpring Inc. (NASDAQ:BYSI) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned about 0.57% of BeyondSpring as of its most recent filing with the Securities & Exchange Commission. 40.29% of the stock is owned by institutional investors.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.